Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Australia Places Order For 10 Million Vaccine Doses For H1N1 Flu From CSL

This article was originally published in PharmAsia News

Executive Summary

Facing a sharp increase in H1N1 flu cases, Australia has ordered 10 million doses of a yet-to-be-produced vaccine to prevent the disease, produced by the country's biggest biopharma CSL. The government counted more than 100 cases of the flu, prompting it to buy another 1.6 million courses of GlaxoSmithKline's Australian-developed Relenza (zanamivir). The new doses would add to Australia's existing stockpile of 10.3 million antiviral doses. CSL expects its vaccine against the flu to be ready in a few months, but its production would aid less than half of the country's population. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts